Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery.
Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis.
Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00467-019-04341-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Thrombotic Microangiopathy in Pediatric Patients.
Glob Pediatr Health
December 2024
Universidad de Antioquia, Medellín, Colombia.
. Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. .
View Article and Find Full Text PDFA Unique Presentation of Atypical Hemolytic Uremic Syndrome With Unilateral Blindness and Ischemic Stroke: A Case Report.
Cureus
November 2024
Department of Medicine, Dr. Baba Saheb Ambedkar Medical College and Hospital, New Delhi, IND.
This report describes a rare presentation of atypical hemolytic uremic syndrome with multi-system involvement, including unilateral blindness and stroke. Only a few cases of atypical hemolytic uremic syndrome with unilateral blindness as a presentation have been reported and all have been attributed to central retinal artery obstruction (CRAO). This is the first described case to our knowledge of atypical hemolytic uremic syndrome presenting with unilateral blindness, which was caused by grade four hypertensive retinopathy.
View Article and Find Full Text PDFBackground: Atypical Hemolytic Uremic Syndrome (aHUS) is categorized as a thrombotic microangiopathy (TMA), which arises due to abnormal or unregulated complement pathway activation. While the disease frequently affects renal blood vessels, it can also involve multiple other organ systems. This review examines the prevalence and clinical outcomes of aHUS patients with extrarenal involvement.
View Article and Find Full Text PDF[Atypical spontaneous bacterial peritonitis linked to streptococcal toxic shock syndrome].
Dtsch Med Wochenschr
January 2025
Allgemein- und Viszeralchirurgie, HELIOS Klinik Attendorn: Akademisches Lehrkrankenhaus der Philipps-Universität Marburg, Attendorn, Deutschland.
Anamnesis And Clinical Examination: A 59-year-old female patient with an unremarkable medical history presented with watery diarrhea, severe lower abdominal pain, and fever for approximately 7 days. Physical examination revealed a distended abdomen, bowel sounds were absent, and there was an acute abdomen with generalized guarding and significantly elevated inflammatory markers.
Diagnosis: Abdominal computed tomography showed significant ascites and signs of peritonitis.
Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.
Hematology Am Soc Hematol Educ Program
December 2024
Department of Medicine, Division of Nephrology, Washington University School of Medicine, St. Louis, MO.
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy typically characterized by anemia, thrombocytopenia, and end-organ injury. aHUS occurs due to endothelial injury resulting from overactivation of the alternative pathway of the complement system. The etiology of the dysregulated complement system is either a genetic mutation in 1 or more complement proteins or an acquired deficiency due to autoantibodies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!